Total
0
Shares
Uscom to cover 75pc of U.S. market with new deal
  • Uscom (UCM) has appointed four new U.S. dealers to support a new U.S. sales and marketing strategy
  • The new deals will cover approximately 75 per cent of the U.S. market
  • While Uscom devices have been used by U.S. clinical leaders and centres of excellence, volume sales have been difficult
  • This new structure is to provide cost-effective U.S. sales and marketing network
  • The company is currently in discussions with three more distribution groups, with agreements expected in the next two months.
  • This will provide 100 per cent coverage of mainland U.S.
  • On market close, Uscom is down 3.85 per cent and is selling shares for 12¢ apiece

Uscom (UCM) has appointed four new U.S. dealers to support a new U.S. sales and marketing strategy.

The new deals will cover approximately 75 per cent of the U.S. market, with more than 28 additional direct sale-staff selling Uscom products at no base cost.

Uscom is a medical technology company that specialises in the development of cardiovascular and pulmonary medical devices.

It will now provide direct incentives to dealers by a national network of established regional distributors and is targeted to increase market penetration into the complex, expensive and cloudy U.S. medical market.

The new 28 sale-staff will work directly with Uscom's team.

Executive Chairman Professor Rob Phillips says while China is booming with growth, the U.S. has been slow and expensive.

"This strategic initiative is central to Uscom’s focus on growing global sales channels as our global regulatory approvals approach completion," Rob told the market.

"The U.S. is the largest medical device market in the world but is difficult for international companies to penetrate," he said.

While Uscom devices have been used by U.S. clinical leaders and centres of excellence, volume sales have been difficult. The company says this is due to the lack of hospital representation.

"This new model significantly changes our operations in the U.S. with revenue
anticipated to grow incrementally, and comes following the expansion of our European sales operations last month," he added.

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and the Uscom SpiroSonic digital ultrasonic spirometry technologies.

USCOM 1A provides vital guidance for optimising management of sepsis and the administration of fluid, inotropes and vasoactive therapies in critical care monitoring.

The BP+ SpiroSonic devices improve diagnosis and management of hypertension,
heart failure, asthma, COPD and sleep disorders in the clinical and home care environments.

This new structure is to provide a cost-effective U.S. sales and marketing network for the efficient delivery of the USCOM 1A, and then the new Uscom BP+ and BP+ Reporter, and the five SpiroSonic products once they receive FDA regulatory approval.

Uscom is currently in discussions with three more distribution groups, with agreements expected in the next two months. This will provide 100 per cent coverage of mainland U.S.

On market close, Uscom is down 3.85 per cent and is selling shares for 12¢ apiece.


Subscribe


UCM by the numbers
More From The Market Herald
Genetic Technology’s (ASX:GTG) break-through breast cancer technology to go on sale in 2020

" Genetic Technology’s (ASX:GTG) break-through breast cancer technology to go on sale in 2020

Genetic Technologies (GTG) will start selling its generation 3 breast cancer test next year.
Respiri (ASX:RSH) ticks off significant milestones for wheezo device

" Respiri (ASX:RSH) ticks off significant milestones for wheezo device

Respiri’s (RSH) wheezo device has been given the CE Mark and TGA clearance to be listed in the Australian Therapeutics Goods Register (ARTG).
Zoono (ASX:ZNO) locks in Chinese distribution deal

" Zoono (ASX:ZNO) locks in Chinese distribution deal

Biotech company Zoono’s (ZNO) share price is continuing to rise after announcing it has secured an exclusive Chinese distributor for its product which
Starpharma (ASX:SPL)  progresses to phase 2 DEP cabazitaxel trial

" Starpharma (ASX:SPL) progresses to phase 2 DEP cabazitaxel trial

Starpharma (SPL) has successfully completed the phase 1 component of its phase 1/2 trial for DEP cabazitaxel.